Independent UK medicine guidance
Mounjaro bloating, burping, reflux and sulphur burps
Bloating, burping, wind, indigestion and gastro-oesophageal reflux are all listed as common Mounjaro side effects.
“Sulphur burps” is not a separate medical side effect in the Mounjaro leaflet. It is a popular description for burps with a rotten-egg smell, usually caused by hydrogen sulphide gas in the digestive system.
Why can Mounjaro cause digestive symptoms?
Tirzepatide slows gastric emptying and helps you feel full for longer. When food remains in the stomach for longer, some people experience pressure, bloating, belching or reflux.
Symptoms can be made worse by:
- Large meals
- Eating quickly
- Fatty or fried food
- Fizzy drinks
- Alcohol
- Lying down after eating
- Constipation
- Foods that individually trigger wind or reflux
Sulphur-smelling burps can also occur with a stomach infection, food intolerance or other digestive problem, so they should not always be assumed to be caused by Mounjaro.
What may help?
- Eating smaller meals
- Chewing slowly
- Stopping at the first comfortable feeling of fullness
- Avoiding large meals late in the evening
- Remaining upright after eating
- Reducing fizzy drinks
- Identifying personal trigger foods
- Addressing constipation if it is also present
A pharmacist can advise whether an antacid, alginate or other non-prescription treatment may be suitable. Check first if you take other medicines, as antacids can affect how some treatments are absorbed.
Avoid attempting to “flush out” sulphur burps with extreme diets or unproven supplements.
When should you seek help?
Contact your GP or prescriber if symptoms are frequent, painful, progressively worsening or making it difficult to eat.
Seek urgent help for: severe or persistent abdominal pain, repeated vomiting, a swollen abdomen with an inability to pass poo or wind, vomiting blood, black tar-like poo, chest pain, difficulty swallowing, or signs of dehydration.
Tirzepatide has not been studied extensively in people with severe gastrointestinal disease, including severe gastroparesis. Persistent vomiting, prolonged fullness and difficulty tolerating food should therefore be clinically assessed.
Evidence update, September 2026: SURPASS-CVOT wind, reflux and indigestion figures in the revised SmPC
On 8 September 2026 the electronic medicines compendium (eMC) published a revised Mounjaro Summary of Product Characteristics with a text revision date of 29 August 2026. It adds safety results from SURPASS-CVOT, a large trial that compared tirzepatide with dulaglutide, another injectable diabetes medicine, in adults with type 2 diabetes and established cardiovascular disease. The study-specific figures relevant to this page are:
- Indigestion (dyspepsia): 9.9% of participants taking tirzepatide
- Burping (eructation): 5.4%
- Acid reflux (gastro-oesophageal reflux disease): 5.1%
- Wind (flatulence): 4.8%
- Bloating (abdominal distension): 4.6%
The figures substantiate the frequency categories recorded for that study population in the UK patient leaflet revised in August 2026. They do not add a new side effect and they do not change the advice above about when to seek help.
Source: Mounjaro Summary of Product Characteristics (eMC), text revised 29 August 2026, section 4.8
Related Monj guides
Explore other side effects
Tap a point on the body to jump to that symptom, or choose from the full list below. The pink marker shows where you are now.
© 2026 Medstack Ltd. Written and published by Monj (monj.co.uk). You are welcome to link to this page or quote a short extract with a credit and a link. Republishing the text, page structure, safety-routing design or price data, in whole or in part, including to train or ground an automated system, is not permitted without written permission. See our independence statement and editorial and review policy.
